James Fagelson, MD
Urology · Littleton, CONPI 1558354928
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Boston Scientific at 46.6% of the total. Reporting peaked in 2020 at $1,414 and has fallen 84.0% since, to $226 in 2025. That places this record below the midpoint for urology clinicians in CO, where the typical reported total is $2,878.
Across 66 payments — averaging $52.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Procept Biorobotics Corporation$440
- Dendreon Pharmaceuticals LLC$394
- Astellas Pharma US Inc$205
- Bayer$181
- AbbVie$95
- plus $539 from 14 others
Across 26 payments — averaging $8692.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$226K
What the payments were for
- Consulting fees$1,20035%
- Travel & lodging$44013%
- Food & beverage$1,71749%
- Education$1133%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $1,616 |
| Procept Biorobotics Corporation | 2 | $440 |
| Dendreon Pharmaceuticals LLC | 5 | $394 |
| Astellas Pharma US Inc | 6 | $205 |
| Bayer | 4 | $181 |
| AbbVie(2 entities) | 6 | $95 |
| Sumitomo Pharma America, Inc. | 5 | $87 |
| Olympus America Inc. | 4 | $76 |
| Myovant Sciences Inc. | 3 | $50 |
| Merck | 2 | $45 |
| Accord Healthcare, Inc. | 2 | $38 |
| Laborie Medical Technologies Corp. | 2 | $35 |
| Progenics Pharmaceuticals, Inc. | 2 | $35 |
| Teleflex LLC | 2 | $34 |
| 180 Medical, Inc. | 2 | $33 |
| Myriad Genetic Laboratories, Inc. | 2 | $29 |
| Pfizer | 1 | $24 |
| Johnson & Johnson | 1 | $20 |
| Dornier Medtech America, Inc | 1 | $19 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL BPH$1,200
- AquaBeam Robotic System$411
- PROVENGE$303
- GENERAL - THERAPIES$243
- Xofigo$124
How this compares
$3,470 in reported general payments places this provider in the 50th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 31 | $82,710 |
| GemtesaVibegron | 104 | $79,441 |
| MyrbetriqMirabegron | 108 | $75,478 |
| Tamsulosin Hcl | 759 | $9,675 |
| Potassium Citrate ErPotassium Citrate | 16 | $2,857 |
| Finasteride | 229 | $2,753 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 86 | $1,761 |
| Dutasteride | 26 | $894 |
| Silodosin | 13 | $570 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 111 | $448 |
| Doxazosin Mesylate | 21 | $446 |
| Tadalafil | 26 | $403 |
| Testosterone Cypionate | 11 | $367 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 30 | $244 |
| Oxybutynin Chloride | 11 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $87 | $162,150135 claims |
| Astellas Pharma US IncMyrbetriq | $205 | $75,478108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 225 urology providers in Colorado.
Other urology in Littleton
- Jeffrey SnyderLittleton$9K
- Lawrence KarshDenver$706K
- Alexandra RogersLafayette$476K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Damian SorceParker$224K
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
- John KeferBoulder$68K
- Garrick GreearLongmont$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.